US 5,684,038 AGranted

Composition and process for prevention and treatment of cutaneous immediate hypersensitivity reactions

AssigneeAscent Pharmaceuticals, Inc.

InventorsEmmett Clemente, Robert W. Mendes, Aloysius O. Anaebonam, Mumtaz Ahmed

Life of this patent

Estimating the term…

Loading patent…

Abstract

A process and pharmaceutical composition for the prevention and treatment of cutaneous Type I hypersensitivity reactions in humans is disclosed. The pharmaceutical composition comprises of a chromone compound of the following formula, or a pharmacologically acceptable salt, ester or amide thereof: ##STR1## dissolved or dispersed in a pharmacologically acceptable carrier. In accordance with the process, a preventively or therapeutically effective amount of the composition is topically administered to a human patient, as required; i.e. for prevention the composition is administered to the area of skin susceptible to exposure to antigen and for treatment the composition is administered to the reaction site.

Claims5

Dependent claims

A pharmaceutical composition comprising a therapeutically effective amount the compound 1,3-bis-(2-carboxychromon-5-yloxy)-2-hydroxypropane, or a pharmacologically acceptable salt, ester or amide thereof as the active ingredient dissolved or dispersed in a pharmacologically acceptable carrier;

said pharmacologically acceptable carrier being an oil-in-water emulsion comprising:
(a) a water phase,
(b) an oil phase, and
(c) emulsifier;
said oil phase comprising a wax, squalene, a C.sub.2 -C.sub.4 polypropyleneglycol, a C.sub.12 -C.sub.18 alkyl ether with 2-4 PPG groups per molecule and silicone oil;
and said emulsifier is emulsifying wax and a mixture of a C.sub.2 -C.sub.4 acyl polypropyleneglycol C.sub.12 -C.sub.18 alkyl ether with 2-4 PPG groups per molecule and a polyoxyethyleneglycol C.sub.14 -C.sub.26 ether having an average of 8-12 PEG groups per molecule.

3 more elements

Dependencies are inferred from the claim text.